Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Novartis
Novartis
Taiho Oncology, Inc.
TC Biopharm
Aprea Therapeutics
GCP-Service International West GmbH
Syros Pharmaceuticals
Ensoma
Astellas Pharma Inc
Cellphire Therapeutics, Inc.
Celgene
Merck Sharp & Dohme LLC
Takeda
Janssen Research & Development, LLC
Geron Corporation
Sensei Biotherapeutics, Inc.
Nohla Therapeutics, Inc.
Kiadis Pharma
Kiadis Pharma
Kiadis Pharma
CTI BioPharma
Immune System Key Ltd
medac GmbH
Pfizer
Celgene
Aeglea Biotherapeutics
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Sunesis Pharmaceuticals
Merck Sharp & Dohme LLC
Novartis
Celldex Therapeutics
Cornerstone Pharmaceuticals
TetraLogic Pharmaceuticals
Seagen Inc.
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
BioMAS Ltd
Mesoblast, Ltd.
Texas Oncology Cancer Center
Scios, Inc.
Pfizer
Eisai Inc.
medac GmbH